222 related articles for article (PubMed ID: 19005180)
1. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2.
Schliemann C; Palumbo A; Zuberbühler K; Villa A; Kaspar M; Trachsel E; Klapper W; Menssen HD; Neri D
Blood; 2009 Mar; 113(10):2275-83. PubMed ID: 19005180
[TBL] [Abstract][Full Text] [Related]
2. Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature.
Börschel N; Schwöppe C; Zerbst C; Angenendt L; Kessler T; Klapper W; Giovannoni L; Elia G; Neri D; Berdel WE; Mesters RM; Schliemann C
Leuk Res; 2015 Jul; 39(7):739-48. PubMed ID: 25934049
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
Pretto F; Elia G; Castioni N; Neri D
Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.
Carnemolla B; Borsi L; Balza E; Castellani P; Meazza R; Berndt A; Ferrini S; Kosmehl H; Neri D; Zardi L
Blood; 2002 Mar; 99(5):1659-65. PubMed ID: 11861281
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.
Zegers CM; Rekers NH; Quaden DH; Lieuwes NG; Yaromina A; Germeraad WT; Wieten L; Biessen EA; Boon L; Neri D; Troost EG; Dubois LJ; Lambin P
Clin Cancer Res; 2015 Mar; 21(5):1151-60. PubMed ID: 25552483
[TBL] [Abstract][Full Text] [Related]
6. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.
Schwager K; Hemmerle T; Aebischer D; Neri D
J Invest Dermatol; 2013 Mar; 133(3):751-758. PubMed ID: 23096716
[TBL] [Abstract][Full Text] [Related]
7. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
8. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
[TBL] [Abstract][Full Text] [Related]
9. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
10. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
Eigentler TK; Weide B; de Braud F; Spitaleri G; Romanini A; Pflugfelder A; González-Iglesias R; Tasciotti A; Giovannoni L; Schwager K; Lovato V; Kaspar M; Trachsel E; Menssen HD; Neri D; Garbe C
Clin Cancer Res; 2011 Dec; 17(24):7732-42. PubMed ID: 22028492
[TBL] [Abstract][Full Text] [Related]
11. Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.
Menssen HD; Harnack U; Erben U; Neri D; Hirsch B; Dürkop H
J Cancer Res Clin Oncol; 2018 Mar; 144(3):499-507. PubMed ID: 29327244
[TBL] [Abstract][Full Text] [Related]
12. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
[TBL] [Abstract][Full Text] [Related]
13. Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model.
Rekers NH; Zegers CM; Yaromina A; Lieuwes NG; Biemans R; Senden-Gijsbers BL; Losen M; Van Limbergen EJ; Germeraad WT; Neri D; Dubois L; Lambin P
Radiother Oncol; 2015 Sep; 116(3):438-42. PubMed ID: 26138057
[TBL] [Abstract][Full Text] [Related]
14. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
Kaspar M; Trachsel E; Neri D
Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral immunocytokine treatment results in enhanced antitumor effects.
Johnson EE; Lum HD; Rakhmilevich AL; Schmidt BE; Furlong M; Buhtoiarov IN; Hank JA; Raubitschek A; Colcher D; Reisfeld RA; Gillies SD; Sondel PM
Cancer Immunol Immunother; 2008 Dec; 57(12):1891-902. PubMed ID: 18438664
[TBL] [Abstract][Full Text] [Related]
16. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8
Puca E; Probst P; Stringhini M; Murer P; Pellegrini G; Cazzamalli S; Hutmacher C; Gouyou B; Wulhfard S; Matasci M; Villa A; Neri D
Int J Cancer; 2020 May; 146(9):2518-2530. PubMed ID: 31374124
[TBL] [Abstract][Full Text] [Related]
17. A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo.
Trachsel E; Kaspar M; Bootz F; Detmar M; Neri D
J Invest Dermatol; 2007 Apr; 127(4):881-6. PubMed ID: 17185984
[TBL] [Abstract][Full Text] [Related]
18. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
[TBL] [Abstract][Full Text] [Related]
19. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
Hemmerle T; Neri D
Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
[TBL] [Abstract][Full Text] [Related]
20. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]